Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

‘Modest’ benefit for post-MI T2D glucose monitoring

Key clinical point: Equivocal results were seen regarding the best method to monitor blood glucose after myocardial infarction.

Major finding: Using a Bayesian methodology, the nonsignificant (17-28 minutes per day) increase in time in range tended to favor flash monitoring over fingerstick testing, with less time spent in hypoglycemia.

Study details: LIBERATES is a phase 2b, open-label, parallel arm, multicenter randomized controlled trial of patients with type 2 diabetes who were recruited within 5 days of hospital admission for an acute coronary syndrome.

Disclosures: The LIBERATES trial was funded by grants from the UK National Institute for Health Research and Abbott Diabetes Care. None of the investigators were additionally compensated for their work within the trial. Dr. Stocken had no disclosures in relation to this trial. Dr. Ajjan has received research funding and other financial support from Abbott, Bayer, Eli Lilly, Johnson & Johnson, and Novo Nordisk.

Citation:

Ajjan R et al. EASD 2020. S11 – The LIBERATES Trial.